Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of the IKS04 Regimen Targeting CA242

NCT07738939 is registered in ClinicalTrials.gov with Iksuda Therapeutics Ltd. as lead sponsor.

NCT NCT07738939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07738939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of the IKS04 Regimen Targeting CA242
Lead sponsor
Iksuda Therapeutics Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 31, 2029
Enrollment
120 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer (btc), cholangiocarcinoma, colorectal cancer, gall bladder cancer, gastric cancer (gc), gastro esophageal junctional cancer, gej adenocarcinoma, pdac - pancreatic ductal adenocarcinoma